


COMMENTARY

- 735** **Tobacco Treatment Program Implementation at NCI Cancer Centers: Progress of the NCI Cancer Moonshot-Funded Cancer Center Cessation Initiative**
 Heather D'Angelo, Betsy Rolland, Robert Adsit, Timothy B. Baker, Marika Rosenblum, Danielle Pauk, Glen D. Morgan, and Michael C. Fiore

RESEARCH ARTICLES

- 741** **Thermally Processed Oil Exaggerates Colonic Inflammation and Colitis-Associated Colon Tumorigenesis in Mice**
Jianan Zhang, Xijing Chen, Ran Yang, Qin Ma, Weipeng Qi, Katherine Z. Sanidad, Yeonhwa Park, Daeyoung Kim, Eric A. Decker, and Guodong Zhang
- 751** **Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxy methane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma**
Altaf Mohammed, Naveena B. Janakiram, Venkateshwar Madka, Yuting Zhang, Anil Singh, Laura Biddick, Qian Li, Stanley Lightfoot, Vernon E. Steele, Ronald A. Lubet, Chen S. Suen, Mark Steven Miller, Shizuko Sei, and Chinthalapally V. Rao
- 763** **The NCCN Criterion "Young Age at Onset" Alone is Not an Indicator of Hereditary Breast Cancer in Iranian Population**
Elmira Ebrahimi, Erin Sellars, Reza Shirkoohi, Iraj Harirchi, Reza Ghiasvand, Elham Mohebbi, Kazem Zendehdel, and Mohammad R. Akbari
- 771** **Racial/Ethnic Patterns of Young-Onset Noncardia Gastric Cancer**
Andreana N. Holowatyj, Cornelia M. Ulrich, and Mark A. Lewis
- 781** **Differences in Genome-wide DNA Methylation Profiles in Breast Milk by Race and Lactation Duration**
Brittney C. Davis Lynn, Clara Bodelon, Ruth M. Pfeiffer, Hannah P. Yang, Howard H. Yang, Maxwell Lee, Peter W. Laird, Mihaela Campan, Daniel J. Weisenberger, Jeanne Murphy, Joshua N. Sampson, Eva P. Browne, Douglas L. Anderton, Mark E. Sherman, Kathleen F. Arcaro, and Gretchen L. Gierach

- 791** **Autofluorescence Imaging to Monitor the Progression of Oral Potentially Malignant Disorders**
Katelin D. Cherry, Richard A. Schwarz, Eric C. Yang, Imran S. Vohra, Hawraa Badaoui, Michelle D. Williams, Nadarajah Vigneswaran, Ann M. Gillenwater, and Rebecca Richards-Kortum
- 801** **Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer**
Chelsea Anderson, Hazel B. Nichols, Melissa House, and Dale P. Sandler
- 809** **Effect of Intermittent Versus Continuous Low-Dose Aspirin on Nasal Epithelium Gene Expression in Current Smokers: A Randomized, Double-Blinded Trial**
Linda L. Garland, José Guillen-Rodriguez, Chiu-Hsieh Hsu, Michael Yozwiak, Hao Helen Zhang, David S. Alberts, Lisa E. Davis, Eva Szabo, Carter Merenstein, Julian Lel, Xiaohui Zhang, Hanqiao Liu, Gang Liu, Avrum E. Spira, Jennifer E. Beane, Malgorzata Wojtowicz, and H.-H. Sherry Chow
- 821** **Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms**
Frank A. Sinicrope, Pruthvi R. Velamala, Louis M. Wong Kee Song, Thomas R. Viggiano, David H. Bruining, Elizabeth Rajan, Christopher J. Gostout, Robert E. Kraichely, Navtej S. Buttar, Kenneth W. Schroeder, John B. Kisiel, Mark V. Larson, Seth R. Sweetser, Robert R. Sedlack, Stephen N. Sinicrope, Ellen Richmond, Asad Umar, Gary Della'Zanna, Joni S. Noaeill, Jeffrey P. Meyers, and Nathan R. Foster

 AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

Aspirin, naproxen, and other nonsteroidal anti-inflammatory drugs (NSAIDs) are promising chemopreventive agents for individuals at high risk for colorectal cancer (CRC). However, uptake of chronic and continuous NSAID administration to reduce CRC risk is limited by unwanted side effects. Employing novel dosing regimens and an azoxymethane-induced rat colon cancer model, Mohammed and colleagues found that intermittent use of either aspirin or naproxen was highly effective in preventing the progression of colonic adenoma to adenocarcinoma without serious side effects (see the study beginning on page 751). These findings could ultimately impact the standard of preventive care for patients at the adenoma stage (i.e., in high-risk cohorts) to protect against advancement to invasive adenocarcinoma with intermittent NSAID use. The micrograph on the cover depicts hematoxylin and eosin staining of rat colon crypt, hyperplasia, adenoma, and adenocarcinomas that recapitulate the histological progression of human sporadic CRC.

